NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date (Ascending) | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
70518-3263-04 | 70518-3263 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Oct. 19, 2022 | In Use | |
62332-0620-05 | 62332-0620 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 20, 2022 | In Use | |
62332-0621-17 | 62332-0621 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 20, 2022 | In Use | |
62332-0622-50 | 62332-0622 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 20, 2022 | In Use | |
46708-0620-05 | 46708-0620 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 20, 2022 | In Use | |
46708-0621-17 | 46708-0621 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 20, 2022 | In Use | |
46708-0622-50 | 46708-0622 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 20, 2022 | In Use | |
00310-4535-30 | 00310-4535 | Tremelimumab | IMJUDO | 300.0 mg/15mL | Immunotherapy | Monoclonal Antibody | CTLA-4 | Intravenous | Oct. 21, 2022 | In Use | |
00310-4505-25 | 00310-4505 | Tremelimumab | IMJUDO | 25.0 mg/1.25mL | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | Intravenous | Oct. 21, 2022 | In Use | |
69339-0171-03 | 69339-0171 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct. 24, 2022 | In Use |
Found 10,000 results in 5 milliseconds — Export these results